2007
Primary systemic chemotherapy of invasive lobular carcinoma of the breast
Katz A, Saad ED, Porter P, Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. The Lancet Oncology 2007, 8: 55-62. PMID: 17196511, DOI: 10.1016/s1470-2045(06)71011-7.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaInvasive ductal carcinomaLobular carcinomaSystemic chemotherapyDuctal carcinomaAdjuvant systemic chemotherapyPrimary systemic chemotherapyUse of chemotherapyFrequent histological typeProspective clinical trialsDistinct clinical entityAdjuvant chemotherapyRandomised trialsHistological typeClinical entityBreast diseaseClinical trialsBreast cancerEstrogen receptorChemotherapyInsufficient evidencePrevention strategiesCarcinomaBest treatmentLow grade
2005
Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks
Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks. Journal Of Clinical Oncology 2005, 23: 5983-5992. PMID: 16087943, DOI: 10.1200/jco.2005.06.232.Peer-Reviewed Original ResearchConceptsPrimary systemic chemotherapyWeekly paclitaxelLymph nodesBreast cancerClinical responseFrequent administrationPathologic complete response rateClinical N0 diseaseDoxorubicin/cyclophosphamidePathologic complete remissionSchedule of paclitaxelClinical stage IComplete response rateIIIA breast cancerOperable breast cancerBreast conservation ratesLymph node involvementInvasive breast cancerLymph node statusDoses of paclitaxelFine-needle aspirationN0 diseaseComplete remissionNode involvementSystemic chemotherapy